What Is IGF-1?
Insulin-like Growth Factor 1 (IGF-1) is a peptide hormone that sits at the centre of the body's growth and repair signalling network. Structurally similar to insulin — hence the name — it is a 70-amino-acid protein that functions as one of the primary downstream mediators of growth hormone (GH) activity. While GH is released from the pituitary gland, many of its effects on muscle, bone, and connective tissue are not direct. Instead, GH triggers the liver to produce IGF-1, which then travels through the bloodstream to act on tissues throughout the body.
IGF-1 is not an exotic compound — it is naturally present in every human being from early development onward. Peak levels occur during puberty, when it drives the rapid growth seen in adolescence. Levels decline gradually with age, a pattern that has made IGF-1 a subject of significant interest in ageing research, muscle physiology, and metabolic science.
Researchers also study a modified variant known as IGF-1 LR3 (Long R3 IGF-1). This is a synthetic version where a specific amino acid substitution reduces binding to carrier proteins in the blood, extending the compound's active half-life from minutes to several hours. IGF-1 LR3 is primarily used in laboratory and cell culture research to study IGF-1 receptor signalling without the rapid clearance that makes native IGF-1 harder to work with experimentally.
How It Works — The Mechanism
IGF-1 exerts its effects primarily by binding to the IGF-1 receptor (IGF-1R), a tyrosine kinase receptor found on the surface of muscle cells, connective tissue, bone, and many other cell types. When IGF-1 binds to this receptor, it triggers a cascade of intracellular signalling events that have been studied extensively in the context of muscle growth and repair.
Two signalling pathways are particularly relevant to muscle physiology research. The first is the PI3K-Akt-mTOR pathway, which promotes muscle protein synthesis — the process by which cells build new contractile proteins. Activation of mTOR (mechanistic target of rapamycin) is considered a key checkpoint in initiating hypertrophy, and IGF-1 is one of the upstream signals that can activate this pathway. The second is the MEK-ERK pathway, which is more associated with cell proliferation and survival.
Of particular interest to muscle recovery research is IGF-1's role in activating satellite cells. These are muscle stem cells that lie dormant along muscle fibres. Following damage — from intense exercise or injury — satellite cells are recruited to repair and add to the existing muscle tissue. Research indicates that IGF-1 signalling is involved in both activating these cells and promoting their differentiation into mature muscle fibres, a process central to muscle hypertrophy and regeneration.
IGF-1 also plays a role in suppressing muscle protein breakdown by inhibiting certain components of the ubiquitin-proteasome system, the cellular machinery responsible for degrading damaged or unneeded proteins. The net effect, at least in laboratory models, is a shift toward an anabolic environment — more protein being built, less being broken down.
What Does the Research Say?
The bulk of compelling mechanistic data on IGF-1 comes from animal studies and in vitro (cell culture) research. These studies have produced detailed and reasonably consistent findings, though translating them to human physiology requires care.
In rodent models, IGF-1 overexpression has been shown to produce significant muscle hypertrophy. A widely cited line of research using transgenic mice — often referred to in the literature as the "Schwarzenegger mice" studies — demonstrated that local IGF-1 overexpression in muscle tissue resulted in substantial increases in muscle mass, even in aged animals. These studies, published in journals including the Journal of Cell Biology, were important in establishing the satellite cell activation mechanism described above.
Animal models of wound healing have also consistently shown that IGF-1 administration accelerates tissue repair. Studies involving tendon, cartilage, and skeletal muscle injury have observed faster cellular proliferation and collagen deposition in IGF-1-treated subjects compared to controls. These findings have driven interest in IGF-1's potential role in recovery research.
Human data is considerably more limited and the picture is more complex. Epidemiological studies have observed associations between higher circulating IGF-1 levels and measures of muscle mass and strength in older adults, supporting a role in age-related muscle maintenance. However, observational data cannot establish causation. Controlled intervention trials in healthy humans are sparse, partly due to ethical and regulatory constraints, and partly because IGF-1 has a complex relationship with cancer risk — sustained elevation of IGF-1 has been associated in some population studies with increased risk of certain cancers, though the direction of causality and the relevance of short-term research exposure remain subjects of ongoing investigation.
Studies in individuals with IGF-1 deficiency (such as those with Laron syndrome) have provided useful natural experiments, demonstrating that IGF-1 is necessary for normal muscle development and growth. GH replacement therapy research in GH-deficient adults, which raises IGF-1 levels, has shown improvements in lean body mass and reductions in fat mass, though these findings apply to a clinical deficiency context rather than supraphysiological supplementation in healthy individuals.
Research on IGF-1 LR3 in humans is even more limited, with most data coming from cell culture and animal work. Its extended half-life makes it a useful research tool, but this same property also means its systemic effects are more prolonged and harder to characterise cleanly in a human context.
The honest summary: the mechanistic case for IGF-1's role in muscle protein synthesis, satellite cell activation, and tissue repair is well supported in preclinical models. Human evidence is limited, and the risk-benefit picture in healthy individuals is not well characterised by current research.
Context for Irish Researchers
In Ireland, peptides including IGF-1 and its variants occupy a specific regulatory space. The Health Products Regulatory Authority (HPRA) is the competent authority for medicines and controlled substances in Ireland, operating within the broader EU regulatory framework. IGF-1 is not licensed as a consumer product or dietary supplement in Ireland or anywhere in the EU. It is classified as a research chemical when sold for laboratory and in vitro use, and any supply for human administration would require a medicinal product licence under Irish and EU law.
For Irish researchers, scientists, and sports scientists studying peptide biology, this context matters for how research materials are sourced, stored, and used. Research-grade peptides must come from reputable suppliers who provide third-party analytical certificates (certificate of analysis, or CoA) confirming identity and purity. The Irish research community — including university labs, sports science departments, and independent researchers — has access to legitimate supply channels for research applications, and it is important that sourcing decisions align with applicable legal and institutional frameworks.
Ireland's position within the EU also means that anti-doping regulations apply to competitive athletes. IGF-1 and its analogues are prohibited both in and out of competition under the World Anti-Doping Agency (WADA) Prohibited List, and this prohibition is enforced in Ireland through Sport Ireland's anti-doping programme. This is a relevant consideration for anyone in the Irish sports science space researching or advising on peptide biology.
Key Takeaways
- IGF-1 is a naturally occurring peptide hormone produced primarily in the liver, downstream of growth hormone signalling.
- It activates the PI3K-Akt-mTOR pathway, promoting muscle protein synthesis, and triggers satellite cell activation, which is central to muscle repair and hypertrophy in preclinical research.
- Animal studies consistently demonstrate significant effects on muscle growth and wound healing. Human data is limited and context-specific — most evidence comes from deficiency populations or observational studies.
- IGF-1 LR3 is an extended half-life variant used in laboratory research to study IGF-1 receptor signalling with reduced clearance interference.
- The evidence quality for human anabolic effects is currently insufficient to draw strong conclusions — this is an active and evolving area of research.
- In Ireland, IGF-1 is regulated by the HPRA within the EU medicinal products framework. It is prohibited in competitive sport under WADA regulations enforced by Sport Ireland.
- Any research use should be conducted under appropriate institutional frameworks with properly verified, third-party tested materials.
For research tools, protocol reference guides, and resources covering the broader peptide research landscape in Ireland, visit irishpeptides.ie/free-tools.